# Board Readiness

> Prepare for board service — observer or director — covering fiduciary literacy, board meeting protocol, IC dynamics, governance roles, the relationship between board and CEO, and the practices that distinguish effective board members from passive ones. Reference when offered a board observer or director seat, preparing for board work in a CMO or operator role, or building toward board candidacy.

- Skill: `npbuilds/board-readiness` (Agent Skill, multi-file: 2 files)
- Install (CLI): `npx skillmds@latest add npbuilds/board-readiness`
- Raw SKILL.md: https://api.skillmd.com/api/skills/npbuilds/board-readiness/raw
- Safety review: pending
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Productivity
- Author: npbuilds (https://skillmd.com/u/npbuilds)
- Updated: 2026-09-17
- Page: https://skillmd.com/skills/npbuilds/board-readiness

---


# Board Readiness — Governance Literacy and Effective Service

A board seat — even an observer seat — is a high-leverage role with high downside risk if mishandled. The expectations are specific (fiduciary duties, governance protocols, board-CEO dynamics), the rhythms are formal (quarterly meetings with strict materials cycles), and the pattern-matching by other board members is fast. The senior MD stepping into board work without preparation often makes errors that take a year to recover from. This skill is the prep — what you need to know before the first board meeting.

## Key Concepts

### Director vs Observer vs Advisor

| Role | Voting | Fiduciary Duty | Compensation | Risk |
|---|---|---|---|---|
| **Director** | Yes | Yes (full) | Cash + equity ($30K–$200K+ per board) | Personal liability for company decisions |
| **Observer** | No | Limited | Cash + equity (often modest) | Lower; no voting |
| **Advisor** | No | None | Equity (typically) | Minimal |

Most senior MDs starting board work begin as observers or advisors before taking director seats. Each has distinct expectations and protocols.

### Fiduciary Duties (For Directors)

A director's fiduciary duties:

1. **Duty of care** — Make informed decisions; review materials, ask questions
2. **Duty of loyalty** — Act in the company's interest, not personal interest; disclose conflicts
3. **Duty of good faith** — Act honestly and reasonably

Directors who neglect these can face personal liability. The implications:

- Read every board package thoroughly before the meeting
- Disclose any conflict of interest, even apparent ones
- Don't trade on material non-public information
- Document major decisions and your reasoning

For observers, fiduciary duties are limited but professional duties (confidentiality, good faith) still apply.

### The Board Materials Cycle

Most VC-backed boards run a quarterly cadence:

| Stage | Time Before Meeting | Activity |
|---|---|---|
| **Materials draft** | 2 weeks | CEO and team prepare board package |
| **Board package distributed** | 1 week | Sent to all directors and observers |
| **Pre-read** | 5–7 days | Directors read; ask clarifying questions |
| **Board meeting** | Day 0 | Live discussion (in-person or video) |
| **Minutes distributed** | 1 week after | Official record of decisions |
| **Action follow-ups** | Ongoing | Inter-meeting work between board and team |

The board member who reads the package the morning of the meeting is the bad board member. Read it the day it arrives.

### What's in a Board Package

Standard contents for a venture-backed biotech board package:

- CEO update (narrative; 2–5 pages)
- Financial dashboard (cash, burn, runway, key metrics)
- Pipeline / program updates (clinical, regulatory, manufacturing)
- People update (hiring, departures, comp issues)
- Strategic items (specific decisions or discussions for the board)
- Board resolutions (items requiring board vote)
- Appendices (deep data on programs, financials, etc.)

For a clinical-stage biotech, the pipeline section often dominates; reading it well is core competence for an MD director.

### The Board Meeting Itself

A typical 3-hour board meeting:

| Segment | Time | Function |
|---|---|---|
| **CEO opening** | 15 min | High-level update; tone-setting |
| **Programs / pipeline review** | 60–75 min | Deep on each program; questions |
| **Financial update** | 30 min | Cash position, runway, planning |
| **Strategic discussion** | 30–45 min | Items requiring board input |
| **Board resolutions** | 10–15 min | Formal votes |
| **Executive session** | 15 min | Board only (no team) |

The IC dynamics: the CEO drives; investors-as-directors weigh in heavily on financial and strategic items; independent directors and clinical-MD directors often weigh in heavily on pipeline.

### The Director's Job Between Meetings

The strong director does substantive work between meetings:

- Calls with the CEO 1–2 times between meetings
- Network introductions for the company
- Specific advisory work in the director's area of expertise
- Reading the company's relevant industry materials (papers, competitor announcements)

Boards that experience their members as "show up to meetings" are under-using their boards.

### CEO-Board Relationship

The senior board member maintains a particular stance toward the CEO:

- **Supportive but not deferential.** Backs the CEO publicly; raises concerns privately first.
- **Honest.** Tells the CEO things their team won't.
- **Available.** Responds to CEO calls promptly.
- **Forward-looking.** Brings forward thinking, not just historical critique.

The board member who only critiques is unhelpful; the board member who only cheers is a rubber-stamp. The right stance is "thinking partner with fiduciary perspective."

### Common Failure Modes

| Failure | Looks Like | Fix |
|---|---|---|
| Under-preparation | Reading the package the morning of | Read within 48 hours of distribution |
| Disengaged between meetings | Only shows up at quarterly meetings | Substantive between-meeting contribution |
| Domain over-reach | MD director second-guessing every clinical decision | Add value at the strategic / governance level; the team executes |
| Conflict ambiguity | Not disclosing apparent conflicts | Disclose freely; let the board decide |
| Public-private confusion | Disagreeing with CEO publicly | Disagree privately first; back publicly |
| Materials illiteracy | Doesn't understand financials, cap tables, term sheets | Build the literacy; cross-load with `negotiation-leverage/equity-literacy` |

## Self-Coaching Track

**For your situation (MD → biotech VC/operator, board-track potential):**

1. **Build fiduciary literacy.** Read the basics on Delaware corporate law, director duties, conflict-of-interest standards. NACD (National Association of Corporate Directors) materials are the canonical primer.

2. **Build financial / cap-table literacy.** Cross-load with `negotiation-leverage/equity-literacy` and `investing/archon`. A director who can't read a cap table is incompletely prepared.

3. **Read public board materials.** Many public companies' board materials are partially disclosed in proxies. Read 3–5 to internalize the format.

4. **Shadow a board if possible.** Ask a friendly CEO if you can attend a board meeting as an observer. The live experience teaches faster than reading.

5. **Prepare for the offer.** When a board observer or director seat is offered, evaluate using the optionality / role frame; understand the time commitment, compensation, and liability implications before accepting.

6. **For your first seat, default to high preparation.** Read every package within 48 hours. Show up with 5+ substantive questions. Build between-meeting contribution from day 1.

7. **Mentor up.** Find an experienced board member who'll mentor you through your first year of board service. The compounding learning is enormous.

## Teach / Mentor-Others Track

**When coaching a junior or peer through board readiness:**

1. **The director-observer-advisor distinction matters.** Mentees often conflate them. Walk through the table; the implications are different per role.

2. **Fiduciary duties are not optional knowledge.** Coach mentees to learn the basics before accepting any director seat. NACD materials are a good start.

3. **The materials-discipline is the visible competence.** Coach the 48-hour-read habit. Other directors will notice; the noticing compounds reputation.

4. **Coach against domain over-reach.** MD mentees on biotech boards often want to second-guess every clinical decision. Reframe: governance perspective, not execution; the team executes.

5. **The CEO-board relationship is a craft.** Walk through the supportive-but-not-deferential stance; rehearse the disagree-privately-back-publicly pattern.

6. **Between-meeting contribution distinguishes the strong director.** Coach mentees to plan substantive between-meeting work — calls, intros, advisory — from day 1.

## When This Applies

- Considering a board observer or director seat offer
- Preparing for the first board meeting in a new role
- Preparing for board interactions in a CMO or operator role
- Building credibility toward future board candidacy
- Coaching others on board service

## Cross-Domain Connections

- **executive-presence/executive-communication** — Board materials and discussions are exec-comm intensive
- **executive-presence/meeting-mastery** — Board meetings are a special meeting type
- **negotiation-leverage/equity-literacy** — Board work requires cap-table and financial literacy
- **interview-mastery/executive-interview-prep** — Board candidate interviews share elements
- **investing/archon** — VC-backed company board literacy inherits investing frameworks
- **biotech-venture/asclepius** — Clinical-stage biotech boards require asclepius-grade pipeline literacy
- **trajectory-design/role-archetype-mapping** — Board work is its own archetype